Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash from Financing Activities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash from Financing Activities for 16 consecutive years, with $12.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $12.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.5 million, a 386.18% increase, with the full-year FY2024 number at $6.2 million, up 79.59% from a year prior.
  • Cash from Financing Activities was $12.3 million for Q3 2025 at Plus Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $12.4 million in Q1 2025 to a low of -$776000.0 in Q1 2024.
  • A 5-year average of $4.3 million and a median of $2.7 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 51161.11% in 2021, then crashed 634.34% in 2023.
  • Plus Therapeutics' Cash from Financing Activities stood at $9.2 million in 2021, then plummeted by 98.92% to $99000.0 in 2022, then plummeted by 634.34% to -$529000.0 in 2023, then soared by 1416.26% to $7.0 million in 2024, then skyrocketed by 76.75% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Cash from Financing Activities are $12.3 million (Q3 2025), $2.8 million (Q2 2025), and $12.4 million (Q1 2025).